InterMune's Pirfenidone meets Phase III trial goals

InterMune's (ITMN) Pirfenidone drug met the primary goal of a Phase III trial by significantly reducing the progression of idiopathic pulmonary fibrosis (IPF) or mortality.

"IPF is an irreversible and ultimately fatal disease characterized by progressive loss of lung function due to fibrosis (scarring) in the lungs, which hinders the ability of lungs to absorb oxygen," InterMune explains. IPF's five-year survival rate is 20-40%.

Pirfenidone also met secondary endpoints with improvements in six-minute walk tests and progression-free survival.

InterMune now plans to resubmit an application for FDA authorization of Pirfenidone.

Trading in the firm's shares has been halted. (PR)

From other sites
Comments (2)
  • Ofirschweiger
    , contributor
    Comment (1) | Send Message
    Oh god it will fly high
    25 Feb 2014, 08:32 AM Reply Like
    , contributor
    Comments (7) | Send Message
    tradin at 36 now
    25 Feb 2014, 09:33 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs